327 related articles for article (PubMed ID: 35468147)
1. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection.
Richardson JR; Götz R; Mayr V; Lohse MJ; Holthoff HP; Ungerer M
PLoS One; 2022; 17(4):e0266701. PubMed ID: 35468147
[TBL] [Abstract][Full Text] [Related]
2. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
3. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
4. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
Front Immunol; 2021; 12():730766. PubMed ID: 34630410
[TBL] [Abstract][Full Text] [Related]
5. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
[TBL] [Abstract][Full Text] [Related]
6. The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity.
Liu H; Wei P; Aviszus K; Zhang Q; Linderberger J; Yang J; Liu J; Chen Z; Waheed H; Reynoso L; Downey GP; Frankel SK; Kappler JW; Marrack P; Zhang G
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232627
[TBL] [Abstract][Full Text] [Related]
7. Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.
Jang Y; Cho H; Chun J; Park K; Nowakowska A; Kim J; Lee H; Lee C; Han Y; Lee HJ; Shin HY; Kim YB
Vaccine; 2023 Feb; 41(6):1223-1231. PubMed ID: 36631359
[TBL] [Abstract][Full Text] [Related]
8. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
9. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine.
Huhn G; Poorbaugh J; Zhang L; Beasley S; Nirula A; Brothers J; Welbel S; Wilson J; Gillani S; Weber KM; Morack R; Keckler K; Benschop RJ
PLoS One; 2022; 17(9):e0273323. PubMed ID: 36083883
[TBL] [Abstract][Full Text] [Related]
12. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
Lavezzo E; Pacenti M; Manuto L; Boldrin C; Cattai M; Grazioli M; Bianca F; Sartori M; Caldart F; Castelli G; Nicoletti M; Nieddu E; Salvadoretti E; Labella B; Fava L; Vanuzzo MC; Lisi V; Antonello M; Grimaldi CI; Zulian C; Del Vecchio C; Plebani M; Padoan A; Cirillo DM; Brazzale AR; Tonon G; Toppo S; Dorigatti I; Crisanti A
Genome Med; 2022 Jun; 14(1):61. PubMed ID: 35689243
[TBL] [Abstract][Full Text] [Related]
13. Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.
Jäger M; Sonnleitner ST; Dichtl S; Lafon E; Diem G; Walder G; Lass-Flörl C; Wilflingseder D; Posch W
Front Immunol; 2022; 13():868361. PubMed ID: 35833113
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition.
Walker MR; Podlekareva D; Johnsen S; Leerhøy B; Fougeroux C; Søgaard M; Salanti A; Ditlev SB; Barfod L
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146667
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
17. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
[TBL] [Abstract][Full Text] [Related]
19. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
Rouhani SJ; Yu J; Olson D; Zha Y; Pezeshk A; Cabanov A; Pyzer AR; Trujillo J; Derman BA; O'Donnell P; Jakubowiak A; Kindler HL; Bestvina C; Gajewski TF
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732350
[TBL] [Abstract][Full Text] [Related]
20. Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection.
Augello M; Bono V; Rovito R; Tincati C; d'Arminio Monforte A; Marchetti G
AIDS; 2023 Aug; 37(10):1503-1517. PubMed ID: 37199415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
